Tyra Biosciences shares are trading higher. The company announced that it will host a conference call and webcast to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer.
Portfolio Pulse from Benzinga Newsdesk
Tyra Biosciences shares are trading higher following the announcement of a conference call and webcast to discuss interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer.
October 24, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tyra Biosciences shares are up as the company plans to share interim clinical results of TYRA-300, potentially indicating positive developments in their cancer treatment study.
The announcement of a conference call to discuss interim results suggests potential positive developments in the TYRA-300 study, leading to increased investor interest and a rise in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100